Antieosinophilic activity of simendans

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 1, 2007, Pages 31-38

  Kankaanranta, Hannu ^a,b,c   Zhang, Xianzhi ^a,e   Tumelius, Ritva ^d   Ruotsalainen, Minna ^d   Haikala, Heimo ^d   Nissinen, Erkki ^d   Moilanen, Eeva ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^d ORION CORPORATION   (Finland)

^e INSTITUTE OF BIOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIINFLAMMATORY AGENT; BUDESONIDE; CALCIUM; CASPASE; CASPASE INHIBITOR; DEXTROSIMENDAN; DNA FRAGMENT; FAS ANTIGEN; INTERLEUKIN 5; LEVOSIMENDAN; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OVALBUMIN; SIMENDAN; STRESS ACTIVATED PROTEIN KINASE; TROPONIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL SURVIVAL; DRUG MECHANISM; EOSINOPHILIA; HEART FAILURE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMMUNOPHARMACOLOGY; INFLAMMATION; LOEFFLER PNEUMONIA; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; BRONCHOALVEOLAR LAVAGE FLUID; CASPASES; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA FRAGMENTATION; ENZYME INHIBITORS; EOSINOPHILS; HUMANS; HYDRAZONES; INTERLEUKIN-5; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, INBRED BALB C; OVALBUMIN; POTASSIUM CHANNELS; PULMONARY EOSINOPHILIA; PYRIDAZINES;

EID: 34548864720     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.124057     Document Type: Article

References (42)

1. Bankers-Fulbright JL, Kephart GM, Loegering DA, Bradford AL, Okada S, Kita H, and Gleich GJ (1998) Sulfonylureas inhibit cytokine-induced eosinophil survival and activation. J Immunol 160:5546-5553.
2. + channels. J Leukoc Biol 57:851-855.
3. Beauvais F, Garcia-Mace JL, and Joly F (1998) In vitro effects of Uriage spring water on the apoptosis of human eosinophils. Fundam Clin Pharmacol 12:446-450.
4. Bonny C, Oberson A, Negri S, Sauser C, and Schorderet DF (2001) Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 50:77-82.
5. De Souza PM, Kankaanranta H, Michael A, Barnes PJ, Giembycz MA, and Lindsay MA (2002) Caspase-catalyzed cleavage and activation of Mst1 correlates with eosinophil but not neutrophil apoptosis. Blood 99:3432-3438.
6. Dewson G, Cohen GM, and Wardlaw AJ (2001) Interleukin-5 inhibits translocation of Bax to the mitochondria, cytochrome c release, and activation of caspases in human eosinophils. Blood 98:2239-2247.
7. Druilhe A, Letuve S, and Pretolani M (2003) Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. Apoptosis 8:481-495.
8. Follath F, Cleland JGF, Just H, Papp JGY, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell E-P, et al. (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360:196-202.
9. Gardai SJ, Hoontrakoon R, Goddard CD, Day BJ, Chang LY, Henson PM, and Bratton DL (2003) Oxidant-mediated mitochondrial injury in eosinophil apoptosis: enhancement by glucocorticoids and inhibition by granulocyte-macrophage colonystimulating factor. J Immunol 170:556-566.
10. Gleich GJ (2000) Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 105:651-663.
11. Haikala H, Hyttila-Hopponen M, Nissinen E, Ruotsalainen M, Pippuri A and Lonnberg K (2004) inventors; Orion Corporation, assignee. Anti-inflammatory agents. U.S. patent application publication US 2004/0029870. 2004 Feb 12.
12. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, and Linden I-B (1995) Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 27:1859-1866.
13. Haikala HO, Nore PT, Honkanen EJ, Pystynen JJ, Loennberg KK, Luiro AM, and Pippuri AK (1990) inventors; Orion Yhtymae Oy, assignee. Heterocyclic compounds. United Kingdom patent GB 2228004. 1990 Aug 15.
14. Hall DJ, Cui J, Bates ME, Stout BA, Koenderman L, Coffer PJ, and Bertics PJ (2001) Transduction of a dominant-negative H-Ras into human eosinophils attenuates extracellular signal-regulated kinase activation and interleukin-5-mediated cell viability. Blood 98:2014-2021.
15. Hasala H, Zhang X, Saarelainen S, Moilanen E, and Kankaanranta H (July 11, 2006) c-Jun-N-terminal kinase mediates constitutive human eosinophil apoptosis. Pulm Pharm Ther, Epub ahead of print.
16. Hebestreit H, Dibbert B, Balatti I, Braun D, Schapowal A, Blaser K, and Simon H-U (1998) Disruption of fas receptor signaling by nitric oxide in eosinophils. J Exp Med 187:415-425.
17. Kankaanranta H, De Souza PM, Barnes PJ, Salmon M, Giembycz MA, and Lindsay MA (1999) SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther 290:621-628.
18. Kankaanranta H, Giembycz MA, Barnes PJ, Haddad E-B, Saarelainen S, Zhang X, Moilanen E, and Lindsay MA (2002) Hydrogen peroxide reverses IL-5-afforded eosinophil survival and promotes constitutive human eosinophil apoptosis. Int Arch Allergy Immunol 127:73-78.
19. Kankaanranta H, Ilmarinen P, Zhang X, Nissinen E, and Moilanen E (2006) Antieosinophilic activity of orazipone. Mol Pharmacol 69:1861-1870.
20. Kankaanranta H, Lindsay MA, Giembycz MA, Zhang X, Moilanen E, and Barnes PJ (2000) Delayed eosinophil apoptosis in asthma. J Allergy Clin Immunol 106:77-83.
21. Kankaanranta H, Moilanen E, and Zhang X (2005) Pharmacological regulation of human eosinophil apoptosis. Curr Drug Targets Inflamm Allergy 4:433-445.
22. Lin A and Dibling B (2002) The true face of JNK activation in apoptosis. Aging Cell 1:112-116.
23. Louhelainen M, Vahtola E, Kaheinen P, Leskinen H, Merasto S, Kytö V, Finckenberg P, Colucci WS, Levijoki J, Pollesello P, et al. (2007) Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br J Pharmacol 150:851-861.
24. Manning AM, and Davis RJ (2003) Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2:554-565.
25. Maytin M and Colucci WS (2005) Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol 96 (Suppl):26G-31G.
26. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, et al. (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. Eur Heart J 23:1422-1432.
27. Murray J, Ward C, O'Flaherty JT, Dransfield I, Haslett C, Chilvers ER, and Rossi AG (2003) Role of leukotrienes in the regulation of human granulocyte behaviour: dissociation between agonist-induced activation and retardation of apoptosis. Br J Pharmacol 139:388-398.
28. Nore P, Honkanen E, Bäcström R, Wikberg T, Haikala H, and Haarala J (1992), inventors; Orion Yhtymae OY, assignee. (-)-[[4-(1,4,5,6- Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono]propanedinitrile. International patent application publication WO9212135. 1992 Jul 23.
29. Oldner A, Konrad D, Weitzberg E, Rudehill A, Rossi P, and Wanecek M (2001) Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med 29:2185-2193.
30. Parissis JT, Adamopoulos S, Antiades C, Kostakis G, Rigas A, Kyrzopoulos S, Iliodromitis E, and Kremastinos D (2004) Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93:1309-1312.
31. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. J Biol Chem 269:28584-28590.
32. 2+-sensitization. Eur J Pharmacol 486:1-8.
33. Turner NA, Xia F, Azhar G, Zhang X, Liu L, and Wei JY (1998) Oxidative stress induces DNA fragmentation and caspase activation via the c-jun-NH2-terminal kinase pathway in H9c2 cardiac muscle cells. J Mol Cell Cardiol 30:1789-1801.
34. Vignola AM, Chanez P, Chiappara G, Siena L, Merendino A, Reina C, Gagliardo R, Profita M, Bousquet J, and Bonsignore G (1999) Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis. J Allergy Clin Immunol 103:563-573.
35. Walker A, Ward C, Dransfield I, Haslett C, and Rossi AG (2003) Regulation of granulocyte apoptosis by hemopoietic growth factors, cytokines and drugs: potential relevance to allergic inflammation. Curr Drug Targets Inflamm Allergy 2:339-347.
36. Walsh GM, Sexton DW, and Blaylock MG (2003) Mechanisms of steroid action and resistance in inflammation: corticosteroids, eosinophils and bronchial epithelial cells: new insights into the resolution of inflammation in asthma. J Endocrinol 178:37-43.
37. Wedi B, Raap U, Lewrick H, and Kapp A (1997) Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol 100:536-543.
38. + channel in rat ventricular cells. J Pharmacol Exp Ther 283:375-383.
39. Zangrilli J, Robertson N, Shetty A, Wu J, Hastie A, Fish JE, Litwack G, Peters SP (2000) Effect of IL-5, glucocorticoid, and Fas ligation on Bcl-2 homologue expression and caspase activation in circulating human eosinophils. Clin Exp Immunol 120:12-21.
40. Zhang X, Moilanen E, Adcock IM, Lindsay MA, and Kankaanranta H (2002) Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci 71:1523-1534.
41. Zhang X, Moilanen E, and Kankaanranta H (2000) Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide and beclomethasone. Eur J Pharmacol 406:325-332.
42. Zhang X, Moilanen E, Lahti A, Hamalainen M, Giembycz MA, Barnes PJ, Lindsay MA, and Kankaanranta H (2003) Regulation of eosinophil apoptosis by nitric oxide: role of c-jun-N-terminal kinase and signal transducer and activator of transcription 5. J Allergy Clin Immunol 112:93-101.